LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | XMD11-85h | 0.37 | uM | LJP6 | 72 | hr | 1389 | 4413 | 5445 | 0.8063 | 0.7839 |
| MCF7 | XMD11-85h | 1.11 | uM | LJP6 | 72 | hr | 1389 | 4435 | 5445 | 0.8099 | 0.7847 |
| MCF7 | XMD11-85h | 3.33 | uM | LJP6 | 72 | hr | 1389 | 4145 | 5445 | 0.7560 | 0.7204 |
| MCF7 | XMD11-85h | 10 | uM | LJP6 | 72 | hr | 1389 | 2431 | 5445 | 0.4426 | 0.3089 |
| MCF7 | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 2076 | 5905 | 0.3516 | 0.2121 |
| MCF7 | XMD16-144 | 0.12 | uM | LJP5 | 72 | hr | 1389 | 1767 | 5905 | 0.2995 | 0.1223 |
| MCF7 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1389 | 1804 | 5905 | 0.3054 | 0.1330 |
| MCF7 | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 1389 | 1804 | 5905 | 0.3057 | 0.1335 |
| MCF7 | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 1860 | 5905 | 0.3154 | 0.1503 |
| MCF7 | XMD16-144 | 10 | uM | LJP5 | 72 | hr | 1389 | 721 | 5905 | 0.1218 | -0.2727 |
| MCF7 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 5185 | 5905 | 0.8788 | 0.8801 |
| MCF7 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 5720 | 5905 | 0.9682 | 0.9689 |
| MCF7 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 6206 | 5905 | 1.0514 | 1.0488 |
| MCF7 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1389 | 6611 | 5905 | 1.1195 | 1.1112 |
| MCF7 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 6425 | 5905 | 1.0885 | 1.0832 |
| MCF7 | Erlotinib | 10 | uM | LJP5 | 72 | hr | 1389 | 5477 | 5905 | 0.9272 | 0.9287 |
| MCF7 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1389 | 5921 | 5445 | 1.0878 | 1.0876 |
| MCF7 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1389 | 5776 | 5445 | 1.0587 | 1.0568 |
| MCF7 | Gefitinib | 0.37 | uM | LJP6 | 72 | hr | 1389 | 5783 | 5445 | 1.0616 | 1.0614 |
| MCF7 | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 1389 | 5302 | 5445 | 0.9720 | 0.9697 |
| MCF7 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1389 | 5503 | 5445 | 1.0090 | 1.0074 |
| MCF7 | Gefitinib | 10 | uM | LJP6 | 72 | hr | 1389 | 4654 | 5445 | 0.8533 | 0.8433 |
| MCF7 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 6100 | 5905 | 1.0313 | 1.0276 |
| MCF7 | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 6333 | 5905 | 1.0729 | 1.0688 |
| MCF7 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 5701 | 5905 | 0.9658 | 0.9671 |